Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced new clinical data from the Phase 1b/2 trial of Nana-val in patients with EBV+ R/M NPC and other EBV+ solid tumors and outlined its key 2023 clinical objectives.
Royal Bank of Canada (NYSE:RY) has outperformed the market over the past 20 years by 1.59% on an annualized basis producing an average annual return of 9.49%. Currently, Royal Bank of Canada has a market capitalization of $131.04 billion.